Life/Health M&A Hit $54B in 2025 on 14 Megadeals: What Milliman's Report Means for Actuarial Consulting Pipelines

Having reviewed Milliman's annual M&A reports since 2020, the jump from four to fourteen megadeals in a single year is the kind of structural shift that reshapes actuarial consulting pipelines for the next 18 months. Milliman's Life and Health Insurance M&A: A Review of 2025 and an Outlook, published April 7, 2026, documents a year in which publicly announced deal values surged 150% to approximately $53.9 billion while the total deal count stayed flat at 85 transactions globally. That combination of stable volume and tripled value tells a story that matters deeply for actuaries: the deals getting done are far larger, more complex, and more demanding of actuarial expertise than at any point in the past decade.

For context, the four megadeals (transactions exceeding $1 billion) recorded in 2024 generated roughly $21.6 billion in total announced deal value. In 2025, fourteen transactions crossed the billion-dollar threshold, accounting for the vast majority of the $53.9 billion total. The arithmetic is straightforward: megadeal concentration drove virtually all of the year-over-year value growth. This article breaks down what drove the surge, where the deals happened, and what the downstream actuarial implications look like heading into 2026.

The Megadeal Landscape: Five Transactions That Defined 2025

The concentration of value in a handful of transformative transactions distinguishes 2025 from prior years. Five deals in particular illustrate the range of strategic rationales driving billion-dollar insurance M&A.

Helvetia-Baloise: $11.6 Billion Merger of Equals

The largest life and health deal globally in 2025 was the merger of Swiss insurers Helvetia and Baloise, announced in April 2025 and completed in December. The transaction created the second-largest Swiss insurance group with approximately 20% combined market share in Switzerland, more than 22,000 employees, and CHF 20.1 billion in total premiums (CHF 8.6 billion life, CHF 11.5 billion non-life). The exchange ratio of 1.0119 new Helvetia shares per Baloise share, combined with CHF 350 million in expected pre-tax cost synergies (roughly 80% to be realized by 2028), made this a textbook consolidation play in a mature European market.

From an actuarial perspective, mergers of equals at this scale require exhaustive embedded value reconciliation across two distinct reserving frameworks, assumption sets, and product portfolios. The synergy estimate of CHF 350 million implies significant operational integration, which in practice means harmonizing mortality tables, lapse assumptions, expense loadings, and economic scenario generators across legacy books.

Nippon Life-Resolution Life: $10.6 Billion Cross-Border Acquisition

Nippon Life's acquisition of Resolution Life for $10.6 billion, completed in October 2025, was the largest overseas acquisition by a Japanese insurer in history. Nippon Life had held a 23% stake since 2019 and acquired the remaining approximately 77% for $8.2 billion to $8.4 billion. Resolution Life manages more than $85 billion in reserves across more than four million policies, with Blackstone continuing as investment manager for the private credit portfolio.

This deal exemplifies a pattern that Milliman's report highlights across the Asia section: Japanese insurers are aggressively pursuing U.S. and global life and annuity businesses as domestic demographics limit growth. The actuarial complexity here is substantial. Cross-border deals require reconciling JGAAP and U.S. statutory reserve methodologies, modeling currency risk on the liability side, and validating investment assumptions for a portfolio heavily weighted toward private credit and alternative assets.

Aquarian Capital-Brighthouse Financial: $4.1 Billion

The all-cash acquisition of Brighthouse Financial at $70 per share (a roughly 35% premium) brought one of the largest U.S. annuity and life providers under the Aquarian Capital umbrella. Brighthouse's record Shield Level Annuity sales drove 2025 annuity production to $10.3 billion, making the timing of this acquisition strategically significant. The deal, announced in November 2025 with shareholder approval in February 2026, is expected to close later in 2026.

For pricing actuaries, the Brighthouse deal raises questions about how acquirers value annuity new business pipelines during record sales environments. The $10.3 billion in annuity production represents substantial future liability generation, and the reserve assumptions underpinning that book become a critical due diligence item.

Allianz-BlackRock-T&D Consortium and Viridium: EUR 3.5 Billion

A consortium comprising Allianz, BlackRock, Generali Financial Holdings, Hannover Re, and T&D United Capital acquired Viridium from Cinven for EUR 3.5 billion. Viridium holds approximately 5% market share in Germany with EUR 67 billion in assets under management and 3.4 million policyholders. As one of the top two life consolidators in continental Europe and a top ten globally, Viridium represents the institutionalization of closed-book life insurance management in Europe.

The consortium structure itself is notable for actuaries. Multi-party ownership of a life consolidation platform means multiple stakeholders with potentially different views on reserve adequacy, investment strategy, and run-off assumptions. The actuarial appraisal supporting this transaction would have needed to satisfy diverse capital providers ranging from a traditional insurer (Allianz) to an asset manager (BlackRock) to a reinsurer (Hannover Re).

Additional Megadeals Across the Landscape

Beyond these four, the remaining ten megadeals spanned geographies and product lines. Across all insurance lines (not just life and health), PwC documented seven megadeals totaling $29.6 billion in the second half of 2025 alone, representing just 3% of deal volume but 93% of deal value. McKinsey's analysis of total insurance M&A pegged 2025 deal value at approximately $104 billion across all lines, up from $88 billion in 2024.

Regional Breakdown: Where the Deals Happened

Milliman's regional data reveals starkly different M&A dynamics across geographies, each with distinct actuarial implications.

Region	2025 Deals	2024 Deals	2025 Value	2024 Value	Value Change
North America	28	21	$14.4B	~$14.4B	Flat
Europe	~23	~17	$33.6B	$3.0B	+1,020%
Asia	22	~26	$5.8B	~$2.6B	+119%
Latin America	1	3	$96M	Higher	-68%

Europe: The Outsized Story

Europe dominated 2025 deal value with $33.6 billion, up from just $3.0 billion in 2024, a ten-fold increase driven by seven megadeals including the Helvetia-Baloise merger and the Viridium consortium acquisition. This surpassed the previous European record of $15.6 billion set in 2021. Milliman identifies two structural drivers: the "Danish Compromise" regulation (now made permanent) encouraging bancassurance consolidation, and the continued maturation of the U.K. pension risk transfer market.

For European actuaries, the Danish Compromise has particular significance. By allowing banks to apply a lower risk weight to insurance subsidiaries under certain conditions, it has created favorable economics for bancassurance M&A. The actuarial challenge lies in valuing insurance subsidiaries within banking group capital frameworks, where Solvency II and Basel III intersect in complex ways.

North America: Stable Value, Rising Volume

North America recorded 28 deals (all in the U.S.) with flat aggregate value near $14.4 billion. Five deals exceeded $1 billion. Milliman's report highlights three recurring themes: Japanese buyers pursuing U.S. life and annuity businesses, private equity-backed buyers maintaining their presence, and expansion into employee benefits and group medical stop-loss lines.

The flat value figure masks meaningful composition shifts. Japanese insurers like Nippon Life and Dai-ichi Life (which acquired approximately 15% of London-listed M&G, becoming its largest single shareholder) are pursuing overseas growth as domestic demographics constrain organic expansion. Dai-ichi is reportedly evaluating doubling its overseas investment target to JPY 600 billion (approximately $4.17 billion).

Asia: Fewer Deals, Bigger Checks

Asia's deal count fell 15% to 22 transactions, but deal values jumped 119% to $5.8 billion. India led the region for the fourth consecutive year with seven deals. Milliman notes a shift toward partial stake acquisitions rather than full buyouts, reflecting regulatory preferences and market maturity. India's increase of the foreign investment limit from 74% to 100% may accelerate deal activity in coming years.

The Actuarial Due Diligence Pipeline: Why 14 Megadeals Change Everything

The shift from four to fourteen megadeals in a single year is not simply a headline number. It represents a step change in actuarial consulting demand that will reverberate through the profession for at least the next 18 to 24 months. Each megadeal generates multiple streams of actuarial work, and the aggregate effect of fourteen such transactions running concurrently creates capacity constraints that the consulting market has not faced since the 2021 deal cycle.

Embedded Value and Actuarial Appraisals

Every billion-dollar life insurance transaction requires an actuarial appraisal or embedded value analysis. These engagements typically involve building or validating a full projection model of the in-force book, establishing market-consistent economic assumptions, and deriving a present value of future profits under various scenarios. For a transaction like Nippon Life-Resolution Life, with $85 billion in reserves across multiple jurisdictions, the appraisal work alone can consume dozens of actuarial FTEs over several months.

Milliman itself has been involved in more than 75% of major M&A transactions in the industry over the past decade, representing over $100 billion in transactions. The firm's established methodology for Solvency II Appraisal Value (SII-AV) and traditional embedded value frameworks makes them a natural participant in many of these engagements, but the sheer volume of concurrent megadeals strains even the largest consulting firms' capacity.

Reserve Assumption Validation

Acquiring actuaries must independently validate every material reserve assumption in the target's liability portfolio: mortality improvement scales, lapse and surrender rate curves, expense assumptions, reinvestment rate paths, and (for variable products) policyholder behavior models including dynamic lapse and fund transfer assumptions. For cross-border transactions like the Helvetia-Baloise merger, this validation must bridge different regulatory frameworks and local market conventions.

The current regulatory environment adds complexity. In the U.S., the transition to LDTI (ASU 2018-12) for GAAP reporting and the ongoing evolution of principle-based reserving under VM-20 and VM-21 mean that acquiring actuaries must evaluate reserves under multiple concurrent frameworks. For transactions involving offshore reinsurance structures, the AG 55 framework adds another layer of asset adequacy testing that acquirers need to diligence.

Model Risk Assessment

Megadeals bring model risk to the forefront. When an acquirer is paying $4 billion for Brighthouse Financial or $10.6 billion for Resolution Life, the accuracy of the target's actuarial models is a multi-billion-dollar question. Model validation engagements in the M&A context go beyond standard model governance reviews. They require stress-testing the target's models against the acquirer's assumptions, identifying material differences, and quantifying the economic impact of assumption gaps.

The growing role of private credit and alternative assets in insurance portfolios adds a dimension that was less prominent in prior deal cycles. Nearly 75% of insurers now hold private assets, according to industry surveys, and 91% plan to increase their private market allocations over the next two years. For acquiring actuaries, validating investment return assumptions on illiquid asset classes with limited mark-to-market data is a fundamentally different exercise from traditional fixed-income portfolio analysis.

Block Reinsurance and Pension Risk Transfer: The Adjacent Deal Markets

The megadeal surge in traditional M&A sits alongside two adjacent transaction markets that also demand actuarial expertise: closed block reinsurance and pension risk transfer (PRT).

S&P Global estimates that more than $100 billion in closed block reinsurance transactions closed in the U.S. in 2025. The largest single transaction was Venerable Holdings' acquisition of $51 billion in variable annuities from Corebridge Financial for approximately $2.8 billion. Athene completed its eighth block reinsurance transaction with a deal involving Sony Life's USD-denominated whole life policies, bringing its cumulative Japanese cedant reinsurance volume to approximately $19 billion. Talcott Financial expanded its block reinsurance with Japan Post Insurance by JPY 100 billion in March 2026.

The pension risk transfer market, while slightly below its 2024 record, remained robust at an estimated $45 billion to $50 billion in 2025 (per Aon), with a record 94% of defined benefit pension sponsors with de-risking goals intending to fully divest liabilities. The number of active PRT insurers has doubled to more than 20 over the past decade, and the Brookfield-Just Group acquisition signals continued cross-border consolidation in this space.

For actuaries, these adjacent markets multiply the demand effect of the megadeal surge. A single closed block reinsurance transaction involving $51 billion in variable annuity reserves requires pricing analysis, hedging strategy review, and reserve adequacy testing that can parallel the actuarial workload of a traditional M&A deal.

Private Equity's Expanding Footprint

The role of private equity in life insurance M&A continued to expand in 2025, a trend that Milliman's report and multiple industry outlooks flag as structurally significant. Apollo's Athene platform now manages approximately $274 billion in assets, constituting roughly 50% of Apollo's total $548 billion AUM. KKR's acquisition of Global Atlantic (completed in 2020 for $4.4 billion) grew its insurance AUM from $26 billion to more than $96 billion.

The Aquarian Capital-Brighthouse deal fits this pattern. Founded in 2017, Aquarian has grown through a series of insurance acquisitions, using permanent capital structures to acquire and manage insurance liabilities while deploying assets into higher-yielding alternatives. Deloitte's 2026 insurance outlook characterizes private equity-backed insurance M&A as focused on "block deals, reinsurance, and distribution-driven transactions," with acquirers taking a "measured view of risk, growth, and integration."

For reserving and valuation actuaries, the private equity dimension introduces specific considerations. PE-backed acquirers typically have higher investment return targets that influence reserve discount rates and product pricing. The interaction between complex asset portfolios and statutory reserve requirements creates ongoing regulatory scrutiny, particularly around the NAIC's evolving risk-based capital framework and the treatment of affiliated reinsurance.

2026 Outlook: Stable Trajectory Despite Headwinds

Milliman's outlook for 2026 projects that "global life and health insurance mergers and acquisitions are likely to continue along their current stable trajectory in 2026 and beyond," citing persistent structural drivers despite policy and geopolitical uncertainty. This assessment aligns with PwC's projection that M&A activity will remain "on par with 2025" through at least the first half of 2026.

Several factors support continued deal flow. Japanese insurers have not exhausted their overseas acquisition budgets. The European life consolidation market continues to mature, with additional closed-book portfolios expected to come to market. India's regulatory liberalization may accelerate cross-border interest. And the fundamental driver of U.S. life and annuity M&A (private equity seeking permanent capital through insurance liabilities) shows no signs of abating.

The counterweights are real but unlikely to derail the pipeline. Tariff-related macroeconomic uncertainty, rising interest rate volatility, and tighter regulatory scrutiny of PE-backed insurance deals (including ongoing NAIC initiatives around affiliated reinsurance and complex asset-backed reserves) may slow or complicate specific transactions. But the structural demand for life insurance consolidation, closed-book management, and cross-border diversification is deeply embedded in the industry's economics.

Deloitte describes the 2026 outlook as "more balanced than exuberant," with insurers taking a "measured view of risk, growth, and integration." For actuaries, this measured pace may actually be preferable to a deal frenzy: it allows more time for thorough due diligence, careful reserve assumption validation, and proper model risk assessment. The quality of actuarial work in M&A transactions matters most when deal complexity is high and execution timelines allow for rigor rather than shortcuts.

What This Means for Actuarial Careers

The M&A cycle creates specific career implications across experience levels. For senior actuaries with valuation or reserving backgrounds, the current environment offers premium compensation in advisory roles. M&A due diligence engagements require actuaries who can evaluate reserves under multiple frameworks (U.S. statutory, GAAP/LDTI, IFRS 17, Solvency II), communicate findings to non-actuarial stakeholders including private equity investors and corporate boards, and make judgment calls on assumption reasonableness under time pressure.

For mid-career actuaries, the pipeline represents an opportunity to transition from operational roles into advisory work. Consulting firms actively recruiting for M&A practice areas prioritize candidates who have hands-on experience with at least one valuation framework and can demonstrate analytical independence.

For exam candidates and early-career actuaries, the sustained M&A pipeline validates the continued relevance of core actuarial competencies in financial risk quantification. The SOA fellowship tracks in Corporate Finance and Enterprise Risk Management, in particular, build directly applicable skills. As carriers accelerate AI-driven workforce restructuring, actuarial roles that require judgment, cross-framework analysis, and stakeholder communication (exactly the skills demanded in M&A advisory) are among the most resilient to automation.

Conclusion

Milliman's 2025 M&A report documents a year in which the life and health insurance deal market fundamentally changed character. The tripling of deal value on flat transaction volume signals a market driven by transformative, complex megadeals rather than incremental bolt-on acquisitions. For actuaries, this shift is unambiguously positive for consulting demand, career opportunities, and the profession's strategic relevance. The fourteen megadeals of 2025, collectively representing tens of billions in reserve liabilities requiring independent actuarial validation, have created the deepest actuarial M&A advisory pipeline in at least a decade.

The question for 2026 and beyond is not whether deal activity will continue (the structural drivers remain firmly in place) but whether the actuarial profession can supply enough experienced practitioners to meet the quality demands of increasingly complex, cross-border, multi-framework transactions. For those actuaries positioned to engage with this cycle, the opportunity is substantial and durable.